-
Recent Posts
- Pattern illustrated in design patent limited to chairs due to prosecution history
- “[P]ost-interference examination period” was RCE time “attributable to Mayo” that reduced time of patent term adjustment (PTA)
- DC grant of SJ of no induced infringement affirmed, exclusion of expert report proper since Phigenix did not “timely disclose its narrowed infringement theory”
- DC grant of SJ to Genentech of no induced infringement affirmed, exclusion of expert report proper since Phigenix did not “timely disclose its narrowed infringement theory”
- Board properly decided to deny institution and dismiss IPRs on SAS remand instead of instituting on all grounds
Recent Comments
Categories
- America Invents Act
- Analgous Art
- Anticipation (35 USC 102)
- Antitrust
- Appeal
- Arbitration
- Article III disputes
- Assignment / Ownership
- Attorney's Fees
- Best mode
- Biosimilars
- Business methods
- Certificate of Correction
- Claim
- Claim Construction
- Claim Differentiation
- Claim Preclusion
- Claim Vitiation
- Collateral estoppel
- Conception and Reduction to Practice
- Contributory Infringement
- Copyright
- Covered Business Method Reviews
- Damages
- Derivation of Invention
- Design Patents
- Diligence
- Disclaimers
- Discovery
- Doctrine of equivalents
- Double Patenting
- Enablement
- Equitable estoppel
- Exhaustion and Repair
- Experimental Use
- Expert Testimony
- False Marking
- Functional limitations
- Generics / ANDA
- Importation
- Indefiniteness
- Inducement to Infringe
- Inequitable Conduct
- Infringement
- Inherency
- Injunction
- Inter Parties Review (IPR)
- Interference
- International Trade Commission
- Inventorship
- IPR
- Issue Preclusion
- Jurisdiction
- Laches
- Licensing
- Lost Profits
- Malpractice
- Means-plus-function
- Method claims
- Negative Limitations
- Obviousness
- Obviousness-Teaching Away
- On-Sale Bar
- Patent Eligibility (101)
- Patent Exhaustion
- Patent Marking
- Patent Prosecution
- Patent Term Adjustment (PTA)
- Patent Term Extension
- Patentability
- Post-grant review
- Preamble
- Priority
- Privilege
- Procedural Issues
- Product-by-Process
- Prosecution History Estoppel
- Public Accessibility
- Public Use
- Reexamination
- Reissue
- Royalties
- Software
- Summary Judgment
- Trade Dress
- Trade Secret
- Trademarks
- U.S. Supreme Court
- Uncategorized
- Unenforceability
- Unjust enrichment
- Utility
- Venue
- Willfullness
- Written description
Archives
- September 2019
- August 2019
- July 2019
- June 2019
- May 2019
- April 2019
- March 2019
- February 2019
- January 2019
- December 2018
- November 2018
- October 2018
- September 2018
- August 2018
- July 2018
- June 2018
- May 2018
- April 2018
- March 2018
- February 2018
- January 2018
- December 2017
- November 2017
- October 2017
- September 2017
- August 2017
- July 2017
- June 2017
- May 2017
- April 2017
- March 2017
- February 2017
- January 2017
- December 2016
- November 2016
- October 2016
- September 2016
- August 2016
- July 2016
- June 2016
- May 2016
- April 2016
- March 2016
- February 2016
- January 2016
- December 2015
- November 2015
- October 2015
- September 2015
- August 2015
- July 2015
- June 2015
- May 2015
- April 2015
- March 2015
- February 2015
- January 2015
- December 2014
- November 2014
- October 2014
- September 2014
- August 2014
- July 2014
- June 2014
- May 2014
- April 2014
- March 2014
- February 2014
- January 2014
- December 2013
- November 2013
- October 2013
- September 2013
- August 2013
- July 2013
- June 2013
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- July 2011
- February 2011
- January 2011
Meta
- America Invents Act Anticipation (35 USC 102) Appeal Article III disputes Assignment / Ownership Attorney's Fees Claim Construction Claim Differentiation Collateral estoppel Damages Doctrine of equivalents Generics / ANDA Indefiniteness Inducement to Infringe Infringement Injunction Inter Parties Review (IPR) Inventorship IPR Means-plus-function Obviousness Obviousness-Teaching Away Patentability Prosecution History Estoppel Reexamination Software Trademarks Uncategorized Willfullness Written description
Copyright Notice
© Patrick J. Halloran, Ph.D., J.D. and lifescienceip.wordpress.com, [2011-2017]. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Patrick J. Halloran, Ph.D., J.D. and lifescienceip.wordpress.com with appropriate and specific direction to the original content.
Category Archives: Prosecution History Estoppel
ITC finding of no indefiniteness or invalidity for anticipation or obviousness affirmed
Guangdong Alison Hi-Tech Co. v. Int. Trade Comm. (ITC), Aspen Aerogels, Inc. Docket No. 2018-2042 DYK, CHEN, STOLL August 27, 2019 Brief Summary: ITC finding of no indefiniteness or invalidity for anticipation or obviousness affirmed. Summary: Guangdong Alison Hi-Tech Co. … Continue reading
Lilly’s Orange Book ‘209 patent regarding administration of pemetrexed not literally infringed, but infringed under DOE
Eli Lilly and Company v. Hospira, Inc., Dr. Reddy’s Laboratories Docket No. 2018-2126, -2127, -2128 LOURIE, MOORE, TARANTO August 9, 2019 Brief Summary: DC literal infringement decision reversed, but infringement under DOE affirmed. Summary: Hospira and Dr. Reddy’s (DRL) appealed … Continue reading
ITC claim construction, written description, and finding of infringement by imported E. coli strains affirmed by Federal Circuit
Ajinomoto Co. et al. v. Int. Trade Commission (ITC) et al. Docket No. 2018-1590, -1629 (ITC No. 337-TA-1005) DYK (C/D), MOORE, TARANTO August 6, 2019 Brief Summary: ITC claim construction, written description, and finding that certain E. coli strains imported … Continue reading
Continental Circuits LLC v. Intel Corporation, et al.
Docket No. 2018-1076 LOURIE, LINN, TARANTO February 8, 2019 Brief summary: DC judgment that Intel did not infringe CC’s asserted patents vacated and remanded due to DC’s erroneous claim construction (e.g., no clear disavowel of claim scope). Summary: CC appealed … Continue reading
Invidior Inc. et al. v. Dr. Reddy’s Laboratories, S.A. et al.
Docket Nos. 2018-2167, -21696 NEWMAN (D), LOURIE, STOLL Nov. 20, 2018 (Non-precedential) Brief summary: DC order granting Invidior’s preliminary injunction reversed and remanded (“‘305 patent expressly disclaimed, through remarks in the specification, solely using conventional top air drying” and “claim … Continue reading
Supernus Pharmaceuticals, Inc. v. TWi Pharmaceuticals, Inc. et al.
Docket No. 2017-2513 O’MALLEY, CLEVENGER, STOLL September 6, 2018 Non-precedential Brief summary: DC finding that TWi’s ANDA to Supernus’s Oxtellar XR® would infringe the asserted OB-listed patents and that the claims are not invalid affirmed. Summary: TWi appealed DC holding … Continue reading
